地诺孕素药物治疗卵巢子宫内膜异位症对囊肿直径、相关疼痛和卵巢储备的影响

doi:10.3969/j.issn.1001-8131.2023.05.008

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (399 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the effects of drug treatment of ovarian endometriosis on cyst diameter,related pain and ovarian reserve,such as the antral follicle count（AFC）and anti-Müllerian hormone（AMH）measurement.Methods A total of 32 patients were selected and all received 6 months of dienogest.Before treatment and at the end of 6 months of treatment,the patient's cyst diameter,number of AFCs of affected ovaries,number of AFCs of unaffected ovaries,AMH and VAS scores were compared.Results The diameter of the cyst before treatment was（4.05±0.75）cm,the AFC of the affected ovaries（4.16±1.66）,and the VAS score（6.80±0.85）were compared with the diameter of the cyst after 6 months of treatment（2.66±0.71）.）cm,AFC of the affected ovary（8.32±2.33）,VAS score（0.87±0.54）,the diameter of the cyst was significantly reduced after 6 months of treatment,the number of AFCs of the affected ovary was significantly increased,and the VAS score was significantly reduced.And the differences were statistically significant（P<0.05）.Drug treatment with dienogest significantly reduced the diameter and associated pain of endometriosis,AFC was significantly improved,and AMH did not change significantly.Conclusion Our findings indicate that carbocysteine has a positive effect on the frequency and duration of acute attacks in patients with bronchiectasis,and it is well tolerated.

Key words： anti-mullerian hormone Sinus follicle count Denoprogesterone Endometriosis Ovarian reserve

Received: 29 September 2022

PACS:

R711.71

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Tian Huazhong

Cite this article:

Tian Huazhong. The Effect of Dienogest in the Treatment of Ovarian Endometriosis on Cyst Diameter Related Pain and Ovarian Reserve[J]. journal1, 2023, 43(5): 20-22.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2023.05.008 OR http://www.hrbyybjb.org.cn/EN/Y2023/V43/I5/20

[1] 唐楠兰,张华.子宫内膜异位症相关性不孕研究进展[J].现代医药卫生,2020,36(05):79-82.
[2] 李欣欣,张奥,全松.子宫内膜异位症体外受精-胚胎移植结局相关影响因素及对策[J].中国实用妇科与产科杂志,2019,35(06):106-110.
[3] Dunselman GA,Vermeulen N,Becker C,et al.ESHRE guideline:management of women with endometriosis[J].Hum Reprod.2014,29(18):400-402.
[4] 宁艳春,韩宝生,刘秀荣,等.子宫内膜异位症不孕患者的卵母细胞形态及体外受精-胚胎移植结局观察[J].山东医药,2019,059(036):61-63.
[5] 梁梦珊,朱耀魁.子宫内膜异位症发病机制的研究现状[J].中华妇幼临床医学杂志(电子版),2021;17(02):138-141.
[6] 贺焱. 评估经阴道超声(TVS)诊断盆腔子宫内膜异位症的价值[J].家庭医药2020;53,(12):21-53.
[7] 门杰,张宇,陈东燕,等.经阴道超声诊断深部浸润型子宫内膜异位症的意义[J].深圳中西医结合杂志,2019,28(16):12-57.
[8] Hart RJ,Hickey M,Maouris P,et al.Excisional surgery versus ablative surgery for ovarian endometriomata[J].Cochrane Database Syst Rev.2008,16(32):45-32.
[9] 王桂业,陈琼,陈新宇,等.单侧和双侧卵巢子宫内膜异位症抗苗勒管激素水平及与年龄变化的关系[J].中国卫生检验杂志,2019;26(14):23-8.
[10] 李清,马建婷.抗苗勒管激素水平在子宫内膜异位症患者中的研究进展[J].中华生殖与避孕杂志,2020,40(08):675-679.
[11] Kasapoglu I,Ata B,Uyaniklar O,et al.Endometrioma-related reduction in ovarian reserve(ERROR):a prospective longitudinal study[J].Fertil Steril.2018,110(29):122-127.
[12] Benaglia L,Somigliana E,Vercellini P,et al.Endometriotic ovarian cysts negatively affect the rate of spontaneous ovulation[J].Hum Reprod.2009,24(2):2183-2186.
[13] Muzii L,Panici PB.Reply:antral follicle count might be underestimated in the presence of an ovarian endometrioma[J].Hum Reprod.2015,30(18):251-252.
[14] 李梅,高丹,封婷,等.2例特殊类型子宫内膜异位症相关性病变引发的思考[J].诊断病理学杂志,2020,27(05):13-17+23.
[15] Lee JH,Song JY,Yi KW,et al.Effectiveness of dienogest for treatment of recurrent endometriosis:multicenter data[J].Reprod Sci.2018;,25(7):1515-1522.
[16] Takenaka M,Yano R,Hiraku Y,et al.Exploratory study of pre-surgical medications with dienogest or leuprorelin in laparoscopic cystec-tomy of endometrial cysts[J].Obstet Gynaecol Res.2015,41(16):1234-1239.
[17] 朱琴,朱加娟,王丽萍,等.抗苗勒管激素在卵巢型子宫内膜异位症术后卵巢功能评估中的价值[J].浙江医学2020,34(23)54-37
[18] Ersahin AA,Arpaci H,Ersahin SS,et al.AFC vs.AMH:prediction of ovarian response in women with endometrioma undergoing controlled ovarian stimulation[J].Eur Rev Med Pharmacol Sci.2017,21(19):2499-2503.